Long-term gene therapy for wet AMD promising

One year follow-up on rAAV.sFt-1 has found no evidence of inflammation, IOP elevation, events, and clinical changes. » Read more

Analysis: Bupropion + open-angle glaucoma risk

Findings could lead to novel therapy, help explain why IOP reduction does not always prevent progression. » Read more

ARMOR update shows increased sesistance

The latest surveillance data on antibiotic resistance trends show increased levels of resistance among certain isolates, warranting ongoing, prospective, multicenter surveillance studies. » Read more

Genotype-directed therapy may help moderate AMD

Genotyping reveals that certain patients with moderate age-related macular degeneration may benefit more from the AREDS formulation than others. » Read more

Efficient R&D pays dividends for physicians, patients

Both Allergan and Valeant Pharmaceuticals have different approaches to R&D. In this forum, Scott M. Whitcup, MD, executive vice president of R&D for Allergan, outlines his company’s position in developing and bringing new products to market. » Read more

Ophthalmic innovation is through R&D partnerships

In his forum, Calvin Roberts, MD, chief medical officer of Bausch + Lomb, also outlines his company’s position in developing and bringing new products to market. » Read more

Downloads

You are subscribed to the Ophthalmology Times Issue Alert.

• Predictors for the number of AMD injections

• B+L report finds resistance of some ocular pathogens has increased in U.S

• Sleep apnea, glaucoma link more prevalent than thought

• Ophthotech, Novartis join for wet AMD treatment